Yi Lin

MD, PhD

Mayo Clinic

Yi Lin, MD, PhD, is a Consultant in Hematology/Oncology at the Mayo Clinic in Rochester, Minnesota, where she is chair of the Cellular Therapeutics Cross-Disciplinary Group. She also has a clinical practice in lymphoid malignancy and research program in cellular immunotherapy

She completed her medical training at the Northwestern University Feinberg School of Medicine in Chicago, Illinois, before completing a residency at the Mayo Clinic College of Medicine.

Dr Lin’s research focuses on cellular therapy, CAR T-cells, cancer vaccination, immunotherapy, myeloma, lymphoma, and amyloidosis.

CAR T-cell therapy in myeloma

Edward Stadtmauer et al.

CAR T-cells for MM: where are we going?

CAR-T treatment outcomes: MM real-world data

Treatment challenges in myeloma

Managing patients that have undergone CAR T-cell therapy

Durable remission at 2 years following CAR-T axi-cel in refractory DLBCL

CAR T-cell updates in lymphoma and myeloma from ASH 2018

Anti-BCMA CAR T-cells in myeloma: what data do we have so far?

ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel

Prophylactic treatment for CAR T-cell toxicity shows promising results

Next-generation CAR T-cell products for 2018

Anti-BCMA CAR T-cells for MM: durable clinical responses with bb2121

The use of CAR T-cells in multiple myeloma

Adam Cohen et al.

ZUMA-1: a pivotal trial of axicabtagene ciloleucel (AXI-CEL; KTE-C19) in patients with NHL

ZUMA-1: a pivotal trial of CAR T-cells in NHL

bb2121: bringing CAR T-cells into the multiple myeloma world